Literature DB >> 16204057

Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.

Chun-Ming Wong1, Judy Wai-Ping Yam, Yick-Pang Ching, Tai-On Yau, Thomas Ho-Yin Leung, Dong-Yan Jin, Irene Oi-Lin Ng.   

Abstract

Deleted in liver cancer (DLC1) is a candidate tumor suppressor gene recently isolated from human hepatocellular carcinoma. Structurally, DLC1 protein contains a conserved GTPase-activating protein for Rho family protein (RhoGAP) domain, which has been thought to regulate the activity of Rho family proteins. Previous studies indicated that DLC1 was frequently inactivated in cancer cells. In the present study, we aimed to characterize the tumor suppressor roles of DLC1 in hepatocellular carcinoma. We showed that DLC1 significantly inhibited cell proliferation, anchorage-independent growth, and in vivo tumorigenicity when stably expressed in hepatocellular carcinoma cells. Moreover, DLC1 expression greatly reduced the motility and invasiveness of hepatocellular carcinoma cells. With RhoGAP-deficient DLC1 mutant (DLC1-K714E), we showed that the RhoGAP activity was essential for DLC1-mediated tumor suppressor function. Furthermore, the 292- to 648-amino acid region and the steroidogenic acute regulatory related lipid transfer domain played an auxiliary role to RhoGAP and tumor suppressor function of DLC1. Taken together, our findings showed that DLC1 functions as a tumor suppressor in hepatocellular carcinoma and provide the first evidence to support the hypothesis that DLC1 suppresses cancer cell growth by negatively regulating the activity of Rho proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204057     DOI: 10.1158/0008-5472.CAN-05-1318

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  66 in total

1.  Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.

Authors:  Lihong Chen; Changdong Liu; Frankie Chi Fat Ko; Naining Xu; Irene Oi-Lin Ng; Judy Wai Ping Yam; Guang Zhu
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

2.  Involvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarity.

Authors:  Wei Yu; Annette M Shewan; Paul Brakeman; Dennis J Eastburn; Anirban Datta; David M Bryant; Qi-Wen Fan; William A Weiss; Mirjam M P Zegers; Keith E Mostov
Journal:  EMBO Rep       Date:  2008-07-25       Impact factor: 8.807

3.  DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.

Authors:  Xuyu Yang; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Cancer Res       Date:  2011-03-03       Impact factor: 12.701

4.  Effect of FAK, DLC-1 gene expression on OVCAR-3 proliferation.

Authors:  Huina Liu; Huirong Shi; Yibin Hao; Guoqiang Zhao; Xiaofeng Yang; Yali Wang; Mei Li; Min Liu
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

5.  DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity.

Authors:  Veenu Tripathi; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Mol Cell Biol       Date:  2012-04-02       Impact factor: 4.272

6.  Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral-mediated Tumor Growth.

Authors:  Nu T Lu; Natalie M Liu; James Q Vu; Darshil Patel; Whitaker Cohn; Joe Capri; Mary Ziegler; Nikita Patel; Angela Tramontano; Roger Williams; Julian Whitelegge; Samuel W French
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

7.  Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function.

Authors:  Yi-Chun Liao; Yi-Ping Shih; Su Hao Lo
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications.

Authors:  Xuyu Yang; Xiaoling Zhou; Paul Tone; Marian E Durkin; Nicholas C Popescu
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

9.  Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.

Authors:  Lo-Kong Chan; Frankie Chi Fat Ko; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

10.  Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues.

Authors:  Ning Li; Yunzhu Long; Xuegong Fan; Hongbo Liu; Cui Li; Lizhang Chen; Zhiming Wang
Journal:  J Exp Clin Cancer Res       Date:  2009-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.